ATE344279T1 - Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors - Google Patents

Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors

Info

Publication number
ATE344279T1
ATE344279T1 AT96945800T AT96945800T ATE344279T1 AT E344279 T1 ATE344279 T1 AT E344279T1 AT 96945800 T AT96945800 T AT 96945800T AT 96945800 T AT96945800 T AT 96945800T AT E344279 T1 ATE344279 T1 AT E344279T1
Authority
AT
Austria
Prior art keywords
ligand
crystals
binding domain
hormone receptor
thyroid hormone
Prior art date
Application number
AT96945800T
Other languages
English (en)
Inventor
Thomas S Scanlan
John D Baxter
Robert J Fletterick
Richard L Wagner
Peter J Kushner
James L Apriletti
Brian L West
Andrew K Shiau
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE344279T1 publication Critical patent/ATE344279T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT96945800T 1995-12-13 1996-12-13 Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors ATE344279T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US854095P 1995-12-13 1995-12-13
US854395P 1995-12-13 1995-12-13
US860695P 1995-12-14 1995-12-14

Publications (1)

Publication Number Publication Date
ATE344279T1 true ATE344279T1 (de) 2006-11-15

Family

ID=27358633

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945800T ATE344279T1 (de) 1995-12-13 1996-12-13 Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors

Country Status (8)

Country Link
US (1) US6236946B1 (de)
EP (1) EP0873361B1 (de)
JP (1) JP2000502086A (de)
AT (1) ATE344279T1 (de)
AU (1) AU717743B2 (de)
CA (1) CA2240024A1 (de)
DE (1) DE69636677D1 (de)
WO (1) WO1997021993A2 (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636677D1 (de) 1995-12-13 2006-12-14 Univ California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
CA2260992C (en) 1996-08-20 2004-03-09 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
WO1999060014A2 (en) * 1998-03-30 1999-11-25 The Regents Of The University Of California Methods and compounds for modulating nuclear receptor coactivator binding
JP2002516983A (ja) * 1998-03-30 2002-06-11 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 核受容体活性を調節するための方法及び化合物
AU2818200A (en) * 1999-03-01 2000-09-21 Karo Bio Ab Homology models of the glucocorticoid receptor
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6516294B1 (en) 1999-07-01 2003-02-04 The Regents Of The University Of California Nuclear receptor for 1α,25-dihydroxyvitamin D3 useful for selection of vitamin D3 ligands and a method therefor
JP2003511467A (ja) 1999-10-14 2003-03-25 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲンレセプターリガンド結合ドメインの結晶構造
US6627660B1 (en) * 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
GB0005689D0 (en) * 2000-03-09 2000-05-03 Schering Ag Crystal
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US20020045578A1 (en) * 2000-05-22 2002-04-18 Sukits Steven F. Solution structure of TNFR-1 DD and uses thereof
US6395784B1 (en) * 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
JP2004509072A (ja) * 2000-06-28 2004-03-25 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的アンドロゲン受容体モジュレーター並びにその同定、設計及び使用方法
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
WO2003043624A1 (en) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003049685A2 (en) * 2001-12-07 2003-06-19 The Regents Of The University Of California Treatment for age-related macular degeneration
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
AU2003251969A1 (en) * 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Compositions and methods involving nuclear hormone receptor site ii
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
EP1567487A4 (de) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Offenkettige, mit prolylharnstoff verwandtemodulatoren der androgenrezeptorfunktion
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
AU2003300852A1 (en) * 2002-12-10 2004-06-30 The Regents Of The University Of California A method for creating specific, high affinity nuclear receptor pharmaceuticals
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1689757B1 (de) 2003-11-12 2014-08-27 Phenomix Corporation Heterocyclische boronsäureverbindungen
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1689383B1 (de) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Neue phosphor enthaltende thyromimetika
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
CA2573848A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (de) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydrochinazolinone als 5ht-modulatoren
EP2527337A1 (de) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Hemmer des 11-Beta-Hydroxysteroid-Dehydrogenase-1-Enzyms
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
CN101291640A (zh) * 2005-06-24 2008-10-22 托马斯·拉文 甲状腺素化合物用于人体烧伤和脂肪沉积的治疗
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
EP2487154B1 (de) 2005-10-31 2013-10-16 Bristol-Myers Squibb Company Pyrrolidinyl-beta-amino-amid-basierte Inhibitoren von Dipeptidylpeptidase IV und Verfahren
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
DK2069352T5 (en) 2006-08-02 2017-04-03 Cytokinetics Inc SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101573340A (zh) 2006-11-01 2009-11-04 百时美施贵宝公司 糖皮质激素受体AP-1和/或NF-κB活性的调节剂及其用途
EP2089355A2 (de) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
WO2008130951A1 (en) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CN101808995A (zh) 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
CN101910171A (zh) 2007-11-01 2010-12-08 百时美施贵宝公司 可用作糖皮质激素受体AP-1和/或者NF-κB活性调节剂的非甾类化合物及其用途
US8187821B2 (en) * 2008-05-08 2012-05-29 University Of Utah Research Foundation Compositions and methods for the modulation of PGRMC1
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
SG174504A1 (en) 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
BRPI1015096A2 (pt) 2009-04-20 2016-05-03 Mitsubishi Tanabe Pharma Corp agonista de receptor beta de hormônio tireoideano
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
EA201200570A1 (ru) 2009-10-09 2012-11-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
CN104825417A (zh) 2009-11-13 2015-08-12 阿斯利康(瑞典)有限公司 立即释放片剂
MX2012005425A (es) 2009-11-13 2012-06-14 Astrazeneca Uk Ltd Formulaciones de metformina de masa reducida.
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (de) 2010-04-23 2015-10-28 Cytokinetics, Inc. Bestimmte aminopyrimidine und aminotriazine, zusammensetzungen daraus und verfahren zu ihrer verwendung
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
IL295438B2 (en) 2011-01-05 2026-05-01 Lexicon Pharmaceuticals Inc Compositions containing and methods for using inhibitors of sodium-glucose cotransporters 1 and 2
EP2892897A1 (de) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
EP2892896B1 (de) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
EP2925735B1 (de) 2012-11-20 2019-03-13 Lexicon Pharmaceuticals, Inc. Inhibitoren der natriumglucose-cotransporter 1
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN103644180B (zh) * 2013-12-04 2015-12-30 苏州凯欧机械科技有限公司 一种卷膜机支架连接管
FR3023177B1 (fr) 2014-07-04 2016-08-12 Centre Nat De La Rech Scient (C N R S) Procede de preparation de co-cristaux par evaporation flash
EP3442997A2 (de) 2016-04-15 2019-02-20 Indiana University Research & Technology Corporation Fgf21-c-endpeptid-optimierung
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
JP7360583B2 (ja) 2017-09-14 2023-10-13 国立研究開発法人理化学研究所 網膜組織の製造方法
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020016335A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
AU2019346497A1 (en) 2018-09-26 2021-04-08 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2020123861A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
CN113784950A (zh) 2019-03-01 2021-12-10 速通医疗公司 新型拟甲状腺素药
WO2020184720A1 (ja) 2019-03-13 2020-09-17 大日本住友製薬株式会社 移植用神経網膜の品質を評価する方法及び移植用神経網膜シート
BR112021025659A2 (pt) 2019-06-27 2022-02-08 Cytokinetics Inc Polimorfo, composição, métodos para preparar o polimorfo e para tratar uma doença associada com disfunção neuromuscular ou não neuromuscular, fraqueza muscular e/ou fadiga muscular, e, kit
AU2020391467A1 (en) 2019-11-29 2022-06-23 Autobahn Therapeutics, Inc. Novel thyromimetics
EP4167986A4 (de) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. Thyromimetika
EP4168384A4 (de) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. Thyromimetika
US20230313133A1 (en) 2020-09-11 2023-10-05 Riken Complex Containing Neural Retina-Containing Cell Aggregates and Matrix, and Method for Manufacturing Same
US20230310614A1 (en) 2020-09-11 2023-10-05 Sumitomo Pharma Co., Ltd. Medium for Tissue for Transplantation
WO2023090427A1 (ja) 2021-11-19 2023-05-25 国立研究開発法人理化学研究所 シート状網膜組織の製造方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
US4741897A (en) 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5171671A (en) 1987-12-02 1992-12-15 The Salk Institute For Biological Studies Retinoic acid receptor composition
US5438126A (en) 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
US5116828A (en) 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5403925A (en) 1989-12-13 1995-04-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleic acids encoding mammalian H-2RIIBP or RXR.sub.β and uses thereof
US5284999A (en) 1990-04-05 1994-02-08 Brigham And Women's Hospital DNA encoding a pituitary-specific thyroid hormone receptor
US5322933A (en) 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
DE69636677D1 (de) 1995-12-13 2006-12-14 Univ California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
CA2260992C (en) 1996-08-20 2004-03-09 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs

Also Published As

Publication number Publication date
DE69636677D1 (de) 2006-12-14
WO1997021993A3 (en) 1997-07-24
AU717743B2 (en) 2000-03-30
AU1821697A (en) 1997-07-03
EP0873361B1 (de) 2006-11-02
JP2000502086A (ja) 2000-02-22
EP0873361A4 (de) 2002-10-23
CA2240024A1 (en) 1997-06-19
EP0873361A2 (de) 1998-10-28
US6236946B1 (en) 2001-05-22
WO1997021993A2 (en) 1997-06-19

Similar Documents

Publication Publication Date Title
DE69636677D1 (de) Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
WO1999026966A3 (en) Nuclear receptor ligands and ligand binding domains
CA2094380A1 (en) Radiolabelling
FI922164A7 (fi) Ligandireseptorien ja ligandien muodostamia komplekseja vastaan suunna ttuja vasta-aineita ja niiden käyttö ligandi-reseptori-määrityksissä
ATE196548T1 (de) Auswählen von agonisten und antagonisten von liganden
AU675804B2 (en) Novel fibronectin receptors
DK0573545T3 (da) Monoklonale antistoffer mod receptor-inducerede bindingssteder
DK0587555T3 (da) Biofunktionel ligand af DTPA-type
DK0708922T3 (da) Identificering af ligander ved selektiv amplifikation af celler transfekteret med receptorer
DE69127791D1 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
FR2542826B1 (fr) Dispositif de verrouillage pour excavateur
DE69231274D1 (de) Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist
IT9019242A0 (it) Composizione ibrida di combustibile liquido in microemulsione acquosa
EA199900409A1 (ru) Растворимые рецепторы бета-лимфотоксина, антитела против рецепторов лимфотоксина и антитела против лимфотоксиновых лигандов как терапевтические агенты для лечения иммунологических заболеваний
NO873271L (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer.
IT8420113A0 (it) Dispositivo a sifone per macchine lavatrici atto a consentire l'uso alternativo di detergente liquido e di detergente in polvere.
ES2091513T3 (es) Procedimiento para la preparacion de indanonas sustituidas y su utilizacion.
ITMI922854A0 (it) Nuovo uso degli antagonisti dei recettori 5-ht3
DK0684835T3 (da) Ligandantagonister til behandling af brystcancer
DK426584D0 (da) Herbicide midler indeholdende fotosyntesehaemmende herbicider i kombination med 1,4-disubstituerede pyrazolderivater
IT8321025V0 (it) Trincia predisposta per l'attacco ad un trattore sia lateralmente che posteriormente.
OA07356A (fr) 3,4-Diamino-1,2,5-thiadiazoles substitués possedant une activité antagoniste du récepteur-H2 de l'histamine.
FR2668771B1 (fr) Acides nucleiques codant pour des polypeptides ayant une activite de recepteur dopaminergique humain et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides.
ATE134988T1 (de) Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen
ATE222777T1 (de) Sequestrierte bilderzeugungsmitteln

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties